Ş. Köse Et Al. , "Non-inferiority of Generic Tenofovir Disoproxil Fumarate/ Emtricitabine, Hivent® to Brand Name, Truvada® in HIV-Infected Patients," Cerrahpaşa Medical Journal , vol.20, no.10, pp.1-7, 2022
Köse, Ş. Et Al. 2022. Non-inferiority of Generic Tenofovir Disoproxil Fumarate/ Emtricitabine, Hivent® to Brand Name, Truvada® in HIV-Infected Patients. Cerrahpaşa Medical Journal , vol.20, no.10 , 1-7.
Köse, Ş., Mete, B., Gündüz, A., Gencer, S., Öztoprak, N., Kurtaran, B., ... Altuntaş Aydın, Ö.(2022). Non-inferiority of Generic Tenofovir Disoproxil Fumarate/ Emtricitabine, Hivent® to Brand Name, Truvada® in HIV-Infected Patients. Cerrahpaşa Medical Journal , vol.20, no.10, 1-7.
Köse, ŞÜKRAN Et Al. "Non-inferiority of Generic Tenofovir Disoproxil Fumarate/ Emtricitabine, Hivent® to Brand Name, Truvada® in HIV-Infected Patients," Cerrahpaşa Medical Journal , vol.20, no.10, 1-7, 2022
Köse, ŞÜKRAN Et Al. "Non-inferiority of Generic Tenofovir Disoproxil Fumarate/ Emtricitabine, Hivent® to Brand Name, Truvada® in HIV-Infected Patients." Cerrahpaşa Medical Journal , vol.20, no.10, pp.1-7, 2022
Köse, Ş. Et Al. (2022) . "Non-inferiority of Generic Tenofovir Disoproxil Fumarate/ Emtricitabine, Hivent® to Brand Name, Truvada® in HIV-Infected Patients." Cerrahpaşa Medical Journal , vol.20, no.10, pp.1-7.
@article{article, author={ŞÜKRAN KÖSE Et Al. }, title={Non-inferiority of Generic Tenofovir Disoproxil Fumarate/ Emtricitabine, Hivent® to Brand Name, Truvada® in HIV-Infected Patients}, journal={Cerrahpaşa Medical Journal}, year=2022, pages={1-7} }